김수완 (서울대학교)

이도엽 (서울대학교)

김수완 (서울대학교)

박성원 (한림대학교)

박준영 (한림대학교)

이근욱 (한림대학교)

김봉수 (한림대학교)

이도엽 (서울대학교)

Inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, is a chronic illness marked by intestinal inflammation and gut microbiota imbalance, with limited treatment options and challenges for long-term care. This study evaluates the therapeutic potential of AcBb, a co-culture of two newly isolated bacterial strains, in a dextran sulfate sodium (DSS)-induced colitis mouse model, exploring mechanisms through metabolic profiling.

Fecal samples from four groups of C57BL/6 mice—healthy control, AcBb-treated healthy, DSS-induced colitis, and AcBb-treated colitis—were analyzed by LC-Orbitrap MS using reversed-phase chromatography in both positive and negative ionization modes. Multivariate analyses, including PCA, PLS-DA, and multiple linear regression, were performed to identify metabolomic differences among groups.

DSS-treated mice exhibited typical IBD traits. AcBb-treated colitis mice demonstrated marked improvements in disease activity index and colon length. AcBb modulates key metabolic pathways, resulting in distinct fecal metabolomic profiles among the groups. Compared to untreated colitis mice, AcBb-treated ones showed significant differences in metabolites linked to IBD molecular markers and phenotypes.

In conclusion, this analysis highlights AcBb's potential therapeutic role and key metabolic signatures, which may advance IBD management and development of live biotherapeutics